[18F] FDG PET/CT and Head and Neck MRI in the Diagnosis and Prognosis of Moroccan Patients With Nasopharyngeal Carcinoma

Amina Gihbid  
Pasteur Institute of Morocco: Institut Pasteur du Maroc  
https://orcid.org/0000-0002-1958-0688

Ghofrane Cherkaoui Salhi  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Imane El alami  
Pasteur Institute of Morocco: Institut Pasteur du Maroc

Hasnaa Belgadir  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Jaafar Ibnohoud  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Wafa Khaali  
Institut Pasteur du Maroc

Nezha Tawfiq  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Nadia Benchakroun  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Karima Bendahhou  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Abdellatif Benider  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Mohammed El Mzibri  
Centre National de l'Energie des Sciences et des Techniques Nucleaires

Rachida Cadi  
University of Hassan II Casablanca Faculty of Science Ain Chock: Universite Hassan II de Casablanca Faculte des Sciences Ain Chock

Naima El Benna  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Amal Guensi  
Ibn Rochd University Hospital Center: Centre Hospitalier Universitaire Ibn Rochd

Meriem Khyatti (✉️ meriem.khyatti@pasteur.ma)  
Institut Pasteur du Maroc
Research Article

Keywords: Nasopharyngeal carcinoma, [18F] FDG PET/CT, HN-MRI, Diagnostic, Prognostic

DOI: https://doi.org/10.21203/rs.3.rs-452991/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Purpose: While nasopharyngeal carcinoma (NPC) management in Morocco is still based on conventional work-ups: a head and neck computed tomography (HN-CT), thoracic and abdominal CT and bone scan, the combination of HN magnetic resonance imaging (HN-MRI) and 2-Deoxy-2-[¹⁸F] fluoro-D-glucose positron emission tomography/computed tomography ([¹⁸F] FDG PET/CT) is now widely used in the diagnostic and follow-up of this malignancy.

Methods: In this prospective study, [¹⁸F] FDG PET/CT and HN-MRI outcomes of 117 NPC patients diagnosed between January 2017 and December 2018 were investigated in order to assess their usefulness in routine management of Moroccan patients with NPC. The concordance between HN-MRI and [¹⁸F] FDG PET/CT in Tumor (T) and Nodal (N) classification was assessed and the association between [¹⁸F] FDG PET/CT metabolic parameters (Tumor- maximum standardized uptake value (T-SUV max), Nodal (N-SUV max), node-tumor SUV ratio (NTR) and distant metastasis (M-SUV max), TNM staging system, NPC stages and patient's survival outcomes was evaluated.

Results: Our results showed a moderate concordance between T-TEP and T-MRI categories with a Cohen kappa coefficient (k) at 0.45, and a mediocre concordance between N-TEP and N-MRI (k=0.3). Metabolic parameters of the [¹⁸F] FDG PET/CT were assessed; N-SUV max values were significantly higher in patients with advanced nodal involvement, with a mean of 7.4, 9.7 and 11.0 for patients with N1, N2 and N3 nodal categories, respectively (p<0.05). overall, N-SUV max, NTR were independent prognostic markers for overall survival and progression free survival in Moroccan NPC patients (p<0.05).

Conclusion: Our findings provide additional evidence into the complementary roles of HN-MRI and [¹⁸F] FDG PET/CT in TNM and overall staging of NPC. To the best of our knowledge, this is the first Moroccan study to highlight N-SUV max and NTR derived from [¹⁸F] FDG-PET/CT as promising metabolic biomarkers for NPC prognosis.

Introduction

Nasopharyngeal carcinoma (NPC) is the second most common head and neck cancer and is characterized by a deep anatomy and a distinct geographical distribution (Chua et al. 2016). NPC is rare in most parts of the world with an annual incidence of < 1/100,000. However, in high endemic areas (southern China, Southeast Asia and Arctic region), the annual incidence of NPC varies between 30 and 80 cases per 100,000 per year (Bray et al. 2018). In Morocco, an intermediate incidence for NPC, the incidence of NPC is 4.2/100,000 in men and 1.2 /100,000 in women yearly (Benider et al. 2012). NPC clinical symptoms are extremely variable and typically non-specific in the early disease stages (I-II) (Lo et al. 2004). Therefore, it remains clinically silent for a long period of time, and more than 60% of NPC patients have advanced loco-regionally stage at diagnosis (III-IV) (Wang et al. 2017). Moreover, it has been widely assumed that early detection of NPC is associated with favorable treatment outcomes and a long survival rate; the 5-year survival rate for patients in early loco-regional stage (Tumor (T) 1, T2, Nodal (N) 0–1) being around 85%, while for patients with advanced loco-regional stages (T3, T4, N2 and N3), it’s estimated at 65% (Lee et al. 2005).
Worldwide, NPC diagnosis is based on tripod: clinical examination with nasopharyngeal endoscopy, radiological imaging and histo-pathological confirmation. Head and neck magnetic resonance imaging (HN-MRI), HN computed tomography (CT), thoracic and abdominal CT and whole-body bone scan are the conventional work-ups (CWUs) currently used for NPC diagnosis and staging (Goh and Lim 2009). Despite their long clinical use, these conventional approaches have a number of limitations. Given that CWUs show limited contrast and can result in small metastatic lesions escape, this may considerably impact disease staging and treatment protocols (Brouwer et al. 2005). Thus, several studies recommended the use of 2-Deoxy-2-[18F] fluoro-D-glucose positron emission tomography/computed tomography ([18F] FDG PET/CT) and HN-MRI as new NPC diagnosis protocols and disease assessment (Brouwer et al. 2005; Liu et al. 2007; King et al. 2015). At diagnosis, [18F] FDG PET/CT derived imaging markers have improved the accuracy of staging (Chan et al. 2018), while they allowed a better assessment of NPC therapy effectiveness in NPC patients after treatment, by providing information on the residual scar mass and hence lowering the chances of treatment completely eradicating tumors (Wei et al. 2016). In this context, various [18F] FDG PET/CT metabolic parameters have been suggested as prognostic markers for NPC, including maximum standardized uptake value (SUV max), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and node-to-tumor SUV ratio (NTR), that can reflect the tumor biologic characteristics and predict patient’s survival (Chan et al. 2010; Moon et al. 2015; Wei et al. 2016). However, further studies are needed to deeply investigate the clinical application modality of [18F] FDG PET/CT metabolic parameters in the management of NPC.

In Morocco, a great attention was given to cancer management and substantial support was accorded to set up facilities with the most developed technologies for both diagnosis and therapy. In this field, two companies have been set up to produce [18F] FDG radioactive tracer by cyclotron technology and there are currently 7 medical centers using the [18F] FDG PET/CT technology, while, others are planned for the next years. This technology is often used in the management of the most prevalent cancers in Morocco, including, lymphoma, lung, breast etc..., but its use in NPC is still limited. The present study was designed to assess the usefulness of HN-MRI and [18F] FDG PET/CT in routine diagnosis and prognosis of NPC for a better management of this disease in Morocco. The concordance between HN-MRI and [18F] FDG PET/CT in Tumor and Nodal classification was assessed and the association between 18F-FDG-PET/CT metabolic parameters (T-SUV max, N-SUV max, NTR and Metastatic (M-SUV max), TNM staging system, NPC stages and patient’s survival outcomes (overall survival (OS), loco-regional recurrence -free survival (LRRFS) and progression free survival (PFS)) were evaluated.

**Materiel And Methods**

Patients’ recruitment and study design

A total of 117 newly diagnosed patients with NPC, were prospectively recruited in Mohammed VI Center for Cancer Treatment in Casablanca-Morocco, between January 2017 and December 2018. Face-to-face interviews were conducted with all patients to collect information on epidemiological data. Clinical data were retrieved from medical records. All included patients underwent whole body [18F] FDG PET/CT or thoraco-abdominopelvic CT scan (TAP-CT) and HN-MRI scanning or HN-CT imaging before treatment. The study
protocol was approved by the Ethics Committee of Ibn Rochd University Hospital, Casablanca - Morocco and written informed consent was obtained from each recruited patient.

Head & neck Magnetic Resonance Imaging (HN-MRI)

HN-MRI was performed in the Radiology Department of 20 August Hospital in Casablanca using the General Electric 1.5 Tesla machine. Axial and coronal T1-fast spin echo sequence, sagittal T2 cube and axial T2 fast spin echo sequence; without frequency selected fat suppression (in the neck for diagnosis of cervical adenopathy areas) and with frequency selected fat suppression (in the nasopharynx to determine local tumor extension); were obtained before injection of the contrast material. Intravenous administration of gadopentetate dimeglumine (Gd-DTPA) (Magnevist; Schering, Berlin, Germany) was done with a dose of 0.1 mmol/kg body weight, and contrast-enhanced fat-suppressed T1 spin echo sequences in axial and coronal planes were performed. All MRI imaging were captured with a section thickness of 4 mm and imaging matrix of 256 × 256. Interpretation and stratification of MRI results were recorded by an expert radiologist and performed from MRI images and reports.

[18F] FDG PET/CT imaging

[18F] FDG PET/CT was conducted in the Nuclear Medicine Department of Ibn Rochd University Hospital, Casablanca. [18F] FDG PET/CT imaging was performed with a PET/CT scanner (Siemens Biograph 6). All patients fasted for at least 6h before the PET/CT. The capillary blood glucose level was < 7mmol/l. [18F] FDG activities ranging from 3.7 to 5.5 MBq/Kg were injected intravenously and images were acquired 60 to 80 minutes later. CT was realized from the head to the proximal mid-thighs before PET acquisition. The hepatic SUV was further used to compare [18F] FDG uptake in lesions using the expected normal liver as a reference; hepatic SUV of 2.5 was used communally as a cut-off for tumor contouring. SUV max values of liver, nasopharynx tumor (T- SUV max), nodes (N- SUV max), metastasis (M- SUV max), and the MTV were calculated using Siemens software's. The NTR was defined as N-SUV max/ T-SUV max. The interpretation of [18F] FDG PET/CT finding was performed directly from PET images, non–contrast-enhanced CT and fused images. Interpretation and stratification of results was performed by two senior nuclear medicine physicians.

Disease staging

Based on radiological and functional imagine, pathological staging was performed according to the 7th edition of the International Union against Cancer / American Joint Committee on Cancer (UICC/AJCC) system. To evaluate [18F] FDG PET/CT and HN-MRI in T and N staging of NPC patients, we used results of 77 patients who paired these two exams. The HN-MRI was considered as the gold standard for Tumor staging and the [18F] FDG PET/CT for nodal staging and distant metastasis.

Post-treatment follow-up and clinical endpoints

All patients received post-treatment follow-up every 3 months during the first year, every 6 months during the second and third years, and annually thereafter. Clinical examinations, nasopharyngeal endoscopy and imaging follow-up were performed routinely according to the clinical evolution of each patient. Overall survival was defined as the interval from the date of diagnosis to the last follow-up or date of death from any
cause. Locoregional recurrence-free survival (LRRFS) was defined as the interval from the date of diagnosis to the first evidence of radiological or histological loco-regional recurrence, death from any cause or last follow-up. Progression free survival (PFS) was defined as the time from the diagnosis to progression of disease, death or last follow-up (whichever occurred first).

**Statistical analysis**

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software version 22.0 (SPSS Inc., Chicago, IL, USA). Descriptive analysis was carried out to characterize patients’ socio-demographic and clinical variables. The concordance between T and N categories was performed using the Cohen kappa coefficient. The kappa coefficient ($\kappa$) was used as a descriptive indicator of concordance and varies between 0 and 1 ($\leq 0.2$: poor concordance; $0.21–0.4$: fair concordance; $0.41–0.6$: moderate concordance; $0.61–0.8$: good concordance and $\geq 0.81$ very good concordance). The association between TNM staging system, NPC stages and $[^{18}\text{F}]$ FDG PET/CT metabolic parameters (T-SUV max, N-SUV max, NTR and M-SUV max) was analyzed using the ANOVA test. The optimal cut-offs of T-SUV max, N-SUV max, and NTR were obtained using the receiver operating characteristic (ROC) curve analysis. OS, LRRFS, and PFS curves were plotted with the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression models to identify the radiological prognostic factors influencing OS, LRRFS, and PFS. Results were expressed as hazard ratios (HRs) with their 95% confidence intervals (CIs). The following variables were entered as covariates into the model: tumor size, nodal classes, metastatic status and overall stages. Statistical significance was assumed at a $p$ value less than 0.05. Only significant factors ($p$-value < 0.05) on univariate analysis were included in multivariate models.

**Results**

**Patients’ characteristics**

The socio-economical and clinical characteristics of the 117 studied patients are presented in Table 1. The mean age of patients was 43.2 with extreme ages of 12 and 80 years old. NPC was more prevalent in men (64.1%) than women (35.9%), with a sex ratio of 1.7. The main symptoms reported by patients at disease onset showed that most patients presented with lymph node syndromes (82.1%) and headache (79.5%) as early-onset symptoms. The other common presenting symptoms were otologic issues and nasal obstruction reported in 70.9% (83/117) and 61.5% (72/117) of patients, respectively. The non-keratinizing undifferentiated carcinoma prevails and was found in 95.7% of patients (112/117). According to the 7th edition of the AJCC/UICC staging system, 23.9% of patients with NPC were classified in group III (28/117) and 65.0% in group IV (76/117). Imaging outcomes showed that most patients had tumor stages T3 (38/117) and T4 (50/117) and nodal stages N1 (30/117) and N2 (52/117). Furthermore, 31.6% (37/117) of patients have already developed metastasis at time of diagnostic. Evaluation of the local extension of nasopharyngeal tumors by HN-MRI showed that out of the 93 patients, 12 patients (12.9%) presented a limited tumor to the nasopharynx area and 81 patients (87.1%) have parapharyngeal tumor extension. Moreover, the tumor involved the bony structure of skull base in 53 patients (57.0%), and neurologic structures in 35 patients (37.6%).
| Characteristics                      | Number of cases | %  |
|-------------------------------------|----------------|----|
| **Gender**                          |                |    |
| Female                              | 42/117         | 35.9 |
| Male                                | 75/117         | 64.1 |
| **Age**                             |                |    |
| \(\leq 32\) years old              | 32/117         | 27.4 |
| \(< 32\) years old                 | 85/117         | 72.6 |
| **Smoking status**                  |                |    |
| No                                  | 100/117        | 85.5 |
| Yes                                 | 17/117         | 14.5 |
| **Drinking status**                 |                |    |
| No                                  | 100/117        | 85.5 |
| Yes                                 | 17/117         | 14.5 |
| **Clinical presentations**          |                |    |
| Headache                            | 93/117         | 79.5 |
| Lymph node syndromes               | 96/117         | 82.1 |
| Unilateral                          | 53/117         | 45.3 |
| Bilateral                           | 43/117         | 36.8 |
| Otologic issues                     | 83/117         | 70.9 |
| Nasal obstruction                   | 72/117         | 61.5 |
| Epistaxis                           | 63/117         | 53.8 |
| Neck swelling                       | 28/117         | 23.9 |
| Trismus                             | 34/117         | 29.1 |
| Neurologic Syndrome                 | 12/117         | 10.3 |
| **Histopathology**                  |                |    |
| Non-keratinizing undifferentiated carcinoma | 112/117 | 95.7 |
| Non-keratinizing differentiated carcinoma | 2/117   | 1.7 |
| Keratinizing squamous cell carcinoma | 1/117   | 0.9 |
| Others                              | 2/117          | 1.7 |
| **Tumor stage**                     |                |    |
| T1                                  | 12/117         | 10.3 |
| T2                                  | 17/117         | 14.5 |
| T3                                  | 38/117         | 32.5 |
| T4                                  | 50/117         | 43.7 |
| Characteristics                                      | Number of cases | %   |
|------------------------------------------------------|-----------------|-----|
| **Nodal stage**                                      |                 |     |
| N0                                                   | 10/117          | 8.5 |
| N1                                                   | 30/117          | 25.6|
| N2                                                   | 52/117          | 44.4|
| N3                                                   | 25/117          | 21.4|
| **Metastatic status**                                |                 |     |
| M0                                                   | 80/117          | 68.4|
| M1                                                   | 37/117          | 31.6|
| **Stage of the disease (NPC stage)**                 |                 |     |
| I                                                    | 2/117           | 1.7 |
| II                                                   | 11/117          | 9.4 |
| III                                                  | 28/117          | 23.9|
| IV                                                   | 76/117          | 65.0|
| **Local extension of nasopharyngeal tumors by HN-MRI**|                 |     |
| Limited tumor to the nasopharynx area                | 12/93           | 12.9|
| Parapharyngeal involvement                           | 81/93           | 87.1|
| Skull base bone invasion                             | 53/93           | 57.0|
| Neurologic involvement                               | 35/93           | 37.6|

Concordance between HN-MRI and $[^{18}F]$ FDG PET/CT in T and N staging

Among the 117 included patients, 77 patients underwent both HN-MRI and $[^{18}F]$-FDG-PET/CT, and were therefore used to evaluate imaging results in order to assess these two techniques in T and N staging accordingly. Tumor staging by HN-MRI showed that 34 patients were classified T4 (44.2%), 25 were classified T3 (32.5%), 12 were classified T2 (15.6%) and 6 were classified T1 (7.8%). T disease staging using the $[^{18}F]$ FDG PET/CT was as follows: 25 patients were classified T4 (33.8%), 29 were T3 (37.7%), 15 were T2 (18.2%) and 8 were classified T1 (10.4%). The $[^{18}F]$ FDG PET/CT correctly classified 59 patients (76%), underestimated 9 patients (11.6%) and overestimated 9 patients (11.6%), which makes a total of 18 misclassified patients (23%). Overall, a moderate concordance was observed between T-TEP and T-MRI categories with a Cohen kappa coefficient at 0.45. Regarding nodal staging, HN-MRI and $[^{18}F]$ FDG PET/CT showed a perfect concordance for N2 class, with 35 patients staged N2 (45.5%), while HN-MRI and $[^{18}F]$ FDG PET/CT did not detect nodal invasion in 10 (13%) and 8 patients (10.4%), respectively. Moreover, HN-MRI detected unilateral nodal involvement (N1) in 18 patients (23.4%) and N3 in 14 patients (18.2%), while $[^{18}F]$ FDG PET/CT detect N1 nodal involvement in 21 patients (27.3%) and N3 in 13 patients (16.9%). This difference between $[^{18}F]$ FDG PET/CT and HN-MRI in N staging was significant with a mediocre degree of concordance (k = 0.3). HN-MRI correctly classified nodal involvement of 71 patients (92%), underestimated nodal involvement of three patients (3.8%), and overestimated nodal involvement of three patients (3.8%), which makes a total of six (7.7 %) misclassified patients (Table 2).
Table 2
Concordance between HN-MRI and $[^{18}\text{F}]$ FDG PET/CT in T and N staging

| Tumor stage | T MRI | T TEP | Nodal stage | N MRI | N TEP |
|-------------|-------|-------|-------------|-------|-------|
| T1          | 6 (7.8%) | 8 (10.4%) | N0          | 10 (13.0%) | 8 (10.4%) |
| T2          | 12 (15.6%) | 15 (18.2%) | K = 0.459   | 18 (23.4%) | 21 (27.3%) |
|             |       |       | p = 0.00    |       |       |
| T3          | 25 (32.5%) | 29 (37.7%) | N2          | 35 (45.5%) | 35 (45.5%) |
| T4          | 34 (44.2%) | 25 (33.8%) | N3          | 14 (18.2%) | 13 (16.9%) |

Association analysis between metabolic $[^{18}\text{F}]$ FDG PET/CT parameters, TNM classes and NPC stage

Overall, the mean T-SUV max of the studied patients was 11.8 (3.30–36.10), the mean N-SUV max was 9.2 (1.50–19.8) and the mean M-SUV max was 7.4 (1.60–21.50). The NTR was also calculated, and showed a mean of 0.82 (0.16 to 1.9). The best cutoffs values for T-SUV max, N-SUV max and NTR were 10.5, 7.9 and 0.82, respectively (Fig. 1). Association analysis between metabolic $[^{18}\text{F}]$ FDG PET/CT parameters, TNM classes and NPC stage was further performed (Table 3). Our data showed that N-SUV max values were significantly higher in patients with advanced nodal involvement, with a mean of 7.4, 9.7 and 11 for patients with N1, N2, and N3 nodal classes, respectively ($p = 0.01$). However, no significant difference was observed between N-SUV max, tumor size, metastatic status and NPC stage ($p > 0.05$). Similarly, no significant associations were found between $[^{18}\text{F}]$ FDG PET/CT metabolic parameters (T-SUV max, M-SUV max, NTR), TNM classes and NPC stage ($p > 0.05$).
Table 3
Association analysis between metabolic $[^{18}\text{F}]\text{FDG PET/CT}$ parameters, TNM classes and NPC stage

| T-SUV max | N-SUV max | NTR | M-SUV max |
|-----------|-----------|-----|-----------|
| N | Mean (range) | | Mean (range) | | Mean (range) | | Mean (range) | |
| Tumor extension | | | | | | | |
| T1 | 11 | 10.0 (4.2–14.3) | 0.03 | 9 | 8.6 (4.3–11.7) | 0.6 | 9 | 0.96 (0.5–1.9) | 0.3 | 4 | 6.7 (3.0–12.2) | 0.1 |
| | T2 | 15 | 9.4 (5.0–18.1) | | 14 | 8.6 (2.9–15.2) | | 14 | 0.90 (0.3–1.6) | | 3 | 6.5 (4.9–8.6) | |
| | T3 | 32 | 11.5 (3.3–25.4) | | 29 | 9.1 (1.5–17.8) | | 29 | 0.81 (0.1–1.9) | | 10 | 5.2 (1.6–13.4) | |
| | T4 | 41 | 13.5 (5.8–36.1) | | 39 | 10.0 (3.4–32.0) | | 39 | 0.76 (0.2–1.7) | | 14 | 9.4 (3.8–21.5) | |
| Nodal involvement | | | | | | | | |
| | N0 | 8 | 10.9 (5.8–13.5) | 0.6 | - | - | - | 0.01 | - | - | 0.1 | - | - | 0.2 |
| | N1 | 26 | 11.0 (3.3–25.4) | | 26 | 7.4 (1.5–16.5) | | 26 | 0.75 (0.16–1.91) | | 4 | 5.1 (1.6–7.8) | |
| | N2 | 41 | 12.3 (4.3–19.8) | | 41 | 9.7 (1.6–15.2) | | 41 | 0.82 (0.26–1.97) | | 13 | 6.8 (4.9–12.6) | |
| | N3 | 24 | 12.5 (5.1–36.1) | | 24 | 11.0 (4.2–32.0) | | 24 | 0.91 (0.52–1.47) | | 14 | 8.6 (1.6–21.5) | |
| Metastatic status | | | | | | | | |
| | M0 | 63 | 12.1 (4.2–36.1) | 0.5 | 55 | 9.1 (1.6–32.0) | 0.5 | 55 | 0.78 (0.26–1.91) | 0.1 | |
| | M1 | 36 | 11.4 (3.3–20.3) | | 36 | 9.7 (1.5–19.8) | | 36 | 0.88 (0.16–1.97) | | |
| Stage of the disease (NPC stage) | | | | | | | | |
| | I | 2 | 11.1 (8.7–13.5) | 0.2 | - | - | 0.4 | - | - | 0.1 | |
### Radiological prognostic factors related to OS of NPC patients

After a mean follow-up time of 37 months (20–54 mo), 66.3% of patients were alive with mean 4-year OS of 22.7 months. In the present study, the evaluation of radiological and metabolic prognostic factors influencing OS was performed. Our results showed that OS was better in patients with N-SUV max < 7.9 versus ≥ 7.9 (mean 38.4 vs. 31.4 mo, respectively; HR, 0.70; 95% CI, 0.48–1.01; \( p = 0.05 \)) and NTR < 0.81 versus ≥ 0.81 (mean 40.4 vs. 26.5 mo, respectively; HR, 0.55; 95% CI, 0.38–0.78; \( p = 0.001 \)); suggesting higher N-SUV max and NTR as an independent poor prognostic factors for NPC. However, no association between T-SUV max, parapharyngeal tumor extension, skull base bone tumor invasion, neurologic involvement and OS was observed among NPC patients (\( p > 0.05 \)) (Table 4).

| Stage | T-SUV max \( \text{max} \) | N-SUV max \( \text{max} \) | NTR \( \text{max} \) | M-SUV max \( \text{max} \) |
|-------|-----------------|-----------------|----------------|-----------------|
| II    | 9               | 8.3 (4.2–13.2)  | 8              | 1.06 (0.32–1.91)|
|       |                 |                 | 8              | 1.06 (0.32–1.91)|
|       |                 |                 | 8              | 1.06 (0.32–1.91)|
| III   | 23              | 12.3 (4.3–25.4) | 20             | 0.78 (0.26–1.18)|
|       |                 |                 | 20             | 0.78 (0.26–1.18)|
| IV    | 65              | 12.2 (3.3–36.1) | 63             | 0.81 (0.16–1.97)|
|       |                 |                 | 63             | 0.81 (0.16–1.97)|
|       |                 |                 | 63             | 0.81 (0.16–1.97)|
| Table 4 | Radiological factors related to OS of NPC patients |
| --- | --- |
| **OS** | | | **Univariate analysis** | **Multivariate analysis** |
| | 4-year rate (%) | Mean (months) | HR (95% CI) | p | HR (95% CI) | p |
| **T-SUV max** | 99 | | | | | |
| < 10.5 | 45 | 59.8% | 33.8 | 1.11 (0.58–2.15) | 0.74 | - | - |
| ≥ 10.5 | 54 | 61.5% | 37.1 | | | | |
| **N-SUV max** | 91 | | | | | |
| < 7.9 | 35 | 70.0% | 38.4 | 0.70 (0.48–1.01) | 0.05 | 0.39 (0.17–0.89) | 0.02 |
| ≥ 7.9 | 56 | 48.9% | 31.4 | | | | |
| **NTR** | 91 | | | | | |
| < 0.81 | 47 | 73.8% | 40.4 | 0.55 (0.38–0.78) | 0.001 | 0.41 (0.18–0.94) | 0.03 |
| ≥ 0.81 | 44 | 38.8% | 26.5 | | | | |
| **Parapharyngeal involvement** | 93 | | | | | |
| No | 12 | 82.5% | 43.8 | 0.76 (0.36–1.56) | 0.4 | - | - |
| Yes | 81 | 67.0% | 40.0 | | | | |
| **Skull base bone invasion** | 93 | | | | | |
| No | 40 | 71.4% | 42.3 | 0.88 (0.59–1.30) | 0.5 | - | - |
| Yes | 53 | 67.1% | 38.9 | | | | |
| **Neurologic involvement** | 93 | | | | | |
| No | 58 | 67.5% | 40.9 | 0.96 (0.65–1.43) | 0.8 | - | - |
| Yes | 35 | 70.6% | 39.5 | | | | |

Radiological prognostic factors related to LRRFS of NPC patients

Univariate analysis showed that LRRFS was not significantly affected by T-SUV max, N-SUV max, NTR and neurologic involvement with HRs of 0.97 (95% CI: 0.42–2.26; p = 0.9), 0.45 (95% CI: 0.17–1.18; p = 0.1), and 0.71 (95% CI: 0.30–1.70; p = 0.4), respectively. Similarly, our results revealed that patients without parapharyngeal tumor extension, skull base bone tumor invasion and neurologic involvement have better LRRFS with a trend of significance, compared to those with parapharyngeal tumor extension, bone tumor
invasion and neurologic involvement: mean 43.4 vs. 40.5 mo, and an HR of 0.60 (95% CI, 0.13–2.61; \( p = 0.4 \)), mean 44.6 vs. 38.6 mo and an HR of 0.51 (95% CI, 0.20–1.28; \( p = 0.1 \)) and mean 41.4 vs. 40.6 mo and an HR of 0.95 (95% CI: 0.39–2.31; \( p = 0.9 \)), respectively (Table 5).

### Table 5
Radiological factors related to LRRFS of NPC patients

| LRRFS | N   | 4-year rate (%) | Mean (months) | Univariate Analysis |
|-------|-----|-----------------|---------------|---------------------|
|       |     |                 |               | HR (95% CI)         | \( p \) |
| T-SUV max | 99  |                 |               |                     |       |
| < 10.5 | 45  | 67.4%           | 39.1          | 0.97 (0.42–2.26)    | 0.9   |
| ≥ 10.5 | 54  | 54.8%           | 40.7          |                     |       |
| N-SUV max | 91  |                 |               |                     |       |
| < 7.9 | 35  | 75.9%           | 42.7          | 0.45 (0.17–1.18)    | 0.1   |
| ≥ 7.9 | 56  | 51.0%           | 37.3          |                     |       |
| NTR | 91  |                 |               |                     |       |
| < 0.81 | 47  | 69.0%           | 39.8          | 0.71 (0.30–1.70)    | 0.4   |
| ≥ 0.81 | 44  | 51.1%           | 38.6          |                     |       |
| Parapharyngeal involvement | 93  |                 |               |                     |       |
| No | 12  | 76.2%           | 43.4          | 0.60 (0.13–2.61)    | 0.4   |
| Yes | 81  | 56.5%           | 40.5          |                     |       |
| Skull base bone invasion | 93  |                 |               |                     |       |
| No | 40  | 68.5%           | 44.6          | 0.51 (0.20–1.28)    | 0.1   |
| Yes | 53  | 59.8%           | 38.6          |                     |       |
| Neurologic involvement | 93  |                 |               |                     |       |
| No | 58  | 68.3%           | 41.4          | 0.95 (0.39–2.31)    | 0.9   |
| Yes | 35  | 47.1%           | 40.6          |                     |       |

Radiological prognostic factors related to PFS of NPC patients

Univariate analysis showed that PFS was significantly shorter among patients with high N-SUVmax (mean 31.0 vs. 21.4 mo; HR, 0.52; 95% CI, 0.29–0.93; \( p = 0.02 \)) and high NTR (mean 30.4 vs. 18.7 mo; HR, 0.46; 95% CI, 0.27–0.79; \( p = 0.003 \)). T-SUVmax, parapharyngeal tumor extension and neurologic involvement were not found to represent a significant prognostic factor for PFS in NPC (\( p = 0.7 \), \( p = 0.3 \) and \( p = 0.2 \), respectively). Of note, a trend of decreased PFS time and rates was observed in patients with skull base bone tumor invasion.
compared to patients with limited tumor (38.0% vs. 51.7%; 27.6 vs 36.3 mo; HR, 0.54; 95% CI, 0.29–1.02; \( p = 0.05 \)) (Table 6).

### Table 6

| PFS | N    | 4-year rate (%) | Mean (months) | Univariate analysis | Multivariate analysis |
|-----|------|-----------------|---------------|---------------------|-----------------------|
|     |      |                 |               | HR (95% CI)         | HR (95% CI)           |
|     |      |                 |               | p                   | p                     |
| T-SUV max | 99 |                |               |                     |                       |
| < 10.5 | 45 | 39.8% | 26.6          | 0.93 (0.55–1.57)    | -                     |
| ≥ 10.5 | 54 | 29.9% | 26.4          | -                   | -                     |
| N-SUV max | 91 |                |               |                     |                       |
| < 7.9 | 35 | 47.8% | 31.0          | 0.52 (0.29–0.93)    | 0.02                  |
| ≥ 7.9 | 56 | 23.2% | 21.4          | 0.46 (0.23–0.90)    | 0.04                  |
| NTR | 91 |                |               |                     |                       |
| < 0.81 | 47 | 46.0% | 30.4          | 0.46 (0.27–0.79)    | 0.003                 |
| ≥ 0.81 | 44 | 18.1% | 18.7          | 0.50 (0.28–0.89)    | 0.01                  |
| Parapharyngeal involvement | 93 |                |               |                     |                       |
| No | 12 | 63.5% | 36.6          | 0.60 (0.21–1.68)    | 0.3                   |
| Yes | 81 | 37.6% | 30.2          | -                   | -                     |
| Skull base bone invasion | 93 |                |               |                     |                       |
| No | 40 | 51.7% | 36.3          | 0.54 (0.29–1.02)    | 0.05                  |
| Yes | 53 | 38.0% | 27.6          | 0.18 (0.07–0.50)    | 0.001                 |
| Neurologic involvement | 93 |                |               |                     |                       |
| No | 58 | 49.3% | 33.2          | 0.69 (0.38–1.25)    | 0.2                   |
| Yes | 35 | 29.3% | 27.6          | -                   | -                     |

Multivariate Analysis for PFS and OS

Only significant prognostic factors identified in univariate analysis for OS and PFS were assessed in the multivariate analysis (Tables 4 and 5). Among all the radiological and metabolic factors studied, we identified
N-SUV max and NTR as independent prognostic factors for both OS and PFS ($p < 0.05$), and skull base bone invasion as independent prognostic factor for PFS in patients with NPC ($p = 0.001$).

**Discussion**

International recommendation demonstrates that when MRI and $^{18}$F FDG PET/CT are available, the other imaging modalities are optional in NPC staging (Ng et al. 2009; Hung et al. 2020). However, in view of the limited access to HN-MRI and $^{18}$F FDG PET/CT, the conventional imaging diagnosis workup remains widely used in the clinical management of Moroccan patients with NPC. A diagnostic strategy based on the combination of HN-MRI and $^{18}$F FDG PET/CT was employed for NPC patients recruited between January 2017 and December 2018 in Mohammed VI Center for Cancer Treatment of Casablanca, and features extracted from these both imaging modalities were investigated to highlight the overall diagnostic and prognostic values of metabolic and radiological combination.

Epidemiologic and clinical characteristics of the 117 NPC patients enrolled in the present study clearly highlight the urgent need of an effective diagnostic and therapeutic strategy. In fact, our results showed that 82.1% of patients were diagnosed with positive lymph nodal, including 52 patients with N2 (44.4%) and 25.6 patients with N3 (21.4%) involvement, suggesting a high risk of distant metastasis and probable low survival rates among these patients. In fact, a significant association has been reported between N2 and N3 involvement and a higher risk of distant failure after treatment ($p < 0.001$) (Mak et al. 2015; Pastor et al. 2018). Moreover, Lee and al. have demonstrated that patients at advanced stage of NPC (T3, T4 and N2, N3) have less than 5 years' survival rate (65%), as compared to patients at an early stage of the disease (85%) (Lee et al. 2005). In NPC, management of distant metastasis is always a challenge. In a meta-analysis enrolling 1774 patients with NPC, $^{18}$F FDG PET/CT was found to be more efficient than the conventional workup for the detection of distant metastases in patients with NPC (Xu et al. 2017). In the present study, the use of $^{18}$F FDG PET/CT in the definition of patients with distant metastasis showed that 31.6% of patients present distant metastasis at diagnosis. Furthermore, despite the aggressive regimen used for the treatment of these patients diagnosed with distant metastasis, the mean survival time didn't exceed 14.4 months (Li et al. 2015). To limit cancer progression and metastasis development, there's an urgent need to set up an early diagnosis and therapeutic strategy to allow a better loco-regional control, prevent the extent of distant metastasis and improve survival rate of NPC patients.

Findings agreed that HN-MRI is preferred over CT and $^{18}$F FDG PET/CT in the evaluation of loco-regional extension of NPC (T), before and during treatment, and in post-treatment surveillance (Mohandas et al. 2014; Li et al. 2015; Hung et al. 2020). Recently, NPC management was improved by the implementation of $^{18}$F FDG PET/CT and derived biological parameters, which were of great help in the initial diagnosis of NPC, the evaluation of clinical response and especially the monitoring of NPC metastasis disease (Wu et al. 2016; Meng et al. 2020). Accordingly, we have tried in this study to highlight the diagnostic and prognostic values of HN-MRI and $^{18}$F FDG PET/CT in Moroccan patients with NPC.

Our data showed significant discrepancies between $^{18}$F FDG PET/CT and HN-MRI findings in the staging of both tumor extension and nodal involvement. Even both $^{18}$F FDG PET/CT and HN-MRI detect the presence of
primary tumors in all patients, considering the HN-MRI as the gold standard for T classification; $[^{18}\text{F}]$ FDG PET/CT correctly classified 59 patients (76%), underestimated 9 patients (11.6%) and overestimated 9 patients (11.6%), making a total of 23% of misclassified patients. Hence, the Cohen kappa coefficient showed moderate concordance between $[^{18}\text{F}]$ FDG PET/CT and HN-MRI in T staging ($r = 0.45$). These results are in agreement with previously reported data indicating that HN-MRI is more sensitive and specific than CT and $[^{18}\text{F}]$ FDG PET/CT in mapping the parapharyngeal space involvement, bone marrow involvement, paranasal sinuses and intracranial extension (King et al. 2008; Li et al. 2019). In this study, a low Cohen kappa coefficient ($k = 0.3$) was obtained for nodal staging, suggesting a mediocre concordance between $[^{18}\text{F}]$ FDG PET/CT and HN-MRI in nodal assessment. However, no discordance was seen between HN-MRI and $[^{18}\text{F}]$ FDG PET/CT for N2 staging; and HN-MRI didn’t detect cervical nodal metastasis in 2 patients and downstage 3 patients (N1 category). These results are consistent with previous studies reporting that both techniques present high specificity (73–97%), but $[^{18}\text{F}]$ FDG PET/CT has a higher sensitivity (97–100%) in the detection of nodes involvement compared to HN-MRI (84–92%) (Mohandas et al. 2014). Nevertheless, Ou et al. reported that retropharyngeal lymph nodes are identified more easily by HN-MRI compared to $[^{18}\text{F}]$ FDG PET/CT, due to the effect of blooming artifact in $[^{18}\text{F}]$ FDG PET/CT that may result in difficulties in differentiating a primary nasopharyngeal tumor burden from a retropharyngeal node. More precaution in the analysis of retropharyngeal nodes areas by the $[^{18}\text{F}]$ FDG PET/CT is therefore required (Ou et al. 2014). Globally, our data suggest a good complementarity between HN-MRI and $[^{18}\text{F}]$ FDG PET/CT for better management of NPC. In this field, it has been established that the use of HN-MRI and $[^{18}\text{F}]$ FDG PET/CT in initial NPC diagnostic allows a more precise clinical staging of patients, which could improve treatment strategies and contribute to increase significantly patient survival (Ou et al. 2014; Meng et al. 2020).

Accumulating data indicate the promising role of metabolic parameters derived from pre-treatment $[^{18}\text{F}]$ FDG PET/CT as a useful prognostic radiological biomarker. In the present prospective study, pretreatment $[^{18}\text{F}]$ FDG PET/CT metabolic parameters (T-SUV max, N- SUV max, and NTR) and HN-MRI tumor invasion were evaluated as predictor biomarkers of OS, LRRFS and PFS.

Scientific evidence suggested that bone invasion and intracranial involvement are strongly related to distant metastasis occurrence and poor survival in NPC (Cheng et al. 2005; Fei et al. 2019). Moreover, the relationship between parapharyngeal space involvement and the occurrence of metastasis is still controversial (Cheng et al. 2005; Mo et al. 2012). Our results with regards to the relationship between nasopharyngeal tumor invasion defined by HN-MRI (Parapharyngeal involvement, bone invasion and intracranial involvement) and survival outcomes showed that skull base bone invasion are an independent prognostic factor for PFS in patients with NPC ($p = 0.001$). Homogenizing the definition of the parapharyngeal space and including a large cohort of patients are needed to confirm this finding.

Overall, the mean T-SUV max, N-SUV max, M-SUV max, and NTR were 11.8, 9.2, 7.4 and 0.82, respectively. Assessing the association between metabolic $[^{18}\text{F}]$ FDG PET/CT parameters, TNM classes and NPC stage, our results revealed that T-SUV max, M-SUV max and NTR were not associated to TNM classes and stage of NPC ($p > 0.05$). These findings are contrary to previous studies, reporting a strong link between metabolic $[^{18}\text{F}]$ FDG
PET/CT parameters, tumor aggressiveness and patient’s survival outcomes (Teo et al. 1996; Schulte et al. 1999; Allal et al. 2002; Xie et al. 2010). Thus, a study on a larger cohort is needed to confirm this finding.

Moreover, our finding showed no significant differences in 4-years OS, LRRFS and PFS of patients with low or high T-SUV max ($p > 0.05$). According to our results univariate analysis demonstrated that T-SUV max can’t be a prognostic metabolic marker for NPC. Though Xie et al. showed that patients with lower T-SUV max, have a significantly better 5-year OS and DFS (Xie et al. 2010). This could be due to the short follow-up period. Several studies suggest that N-SUV max is more important than T-SUV max for prediction of DMFS in NPC patients (Lin et al. 2016) (Türkölmez et al. 2017; Jeong et al. 2017). In another study, Chen et al. reported that a high N-SUV max on pretreatment [$^{18}$F] FDG PET/CT ($> 7.75$) was an independent prognostic factor for worse DMFS in NPC patients (Chen et al. 2015). Furthermore, Türkölmez et al. demonstrated that high T-SUV max and N-SUV max were related to death risk (Türkölmez et al. 2017). Similarly, our results reported that high N-SUV max ($> 9.4$) was significantly associated with poor OS and PFS, with HR of 0.7 (95% CI, 0.48–1.01; $p = 0.05$) and 0.52 (95% CI, 0.29–0.93; $p = 0.02$) for OS and PFS, respectively. In addition, recent evidences have demonstrated that the NTR has a strong correlation with clinical outcomes for lung, esophageal and cervical cancers (Cirak 2011; Chen et al. 2015; Chung et al. 2017). For NPC, the only published study investigating the prognostic value of NTR found that high NTR ($> 0.9181$) could help in risk stratification of patients to identify those at higher risk of distant metastasis ($p < 0.001$) (Hung et al. 2020). In the same line, we observed that NTR was high in patients with distant metastasis (0.90) compared to those without distant metastasis (0.78). Interestingly, multivariate analysis highlights NTR as a strong predictor of 4-years OS and PFS, with HR of 0.41 (95% CI, 0.18–0.94; $p = 0.03$) for OS, and 0.5 (95% CI, 0.28–0.89; $p = 0.01$) for PFS. Further research is however needed to investigate the clinical application modality of [$^{18}$F] FDG PET/CT metabolic parameters in the management of NPC. Currently, the clinical usefulness of hybrid PET/MRI in clinical practice is debated. This modality seems to be a promising tool in terms of increasing the resilience of the radiological images and reducing the diagnostic time of head and neck cancers and many other cancers (Becker and Zaidi 2014; Chen et al. 2020).

**Conclusions**

Our findings clearly provide additional evidence on the complementary roles of HN-MRI and [$^{18}$F] FDG PET/CT in TNM and overall staging of NPC. To the best of our knowledge, this is the first Moroccan study to highlight N-SUV max and NTR derived from [$^{18}$F] FDG PET/CT and Skull base bone invasion defined by HN-MRI as promising metabolic and radiologic biomarkers for NPC prognosis. The present results could be a good basis for future studies confirming the need to introduce these two imaging modalities in the standard management of NPC and the others cancer in Morocco.

**Declarations**

**Acknowledgments**

We are grateful to the staff of Mohammed VI Center for Cancer Treatment, Nuclear Medicine Department at Ibn Rochd University Hospital, Hassan II University and the Department of Radiology, Hopital 20 Août, Ibn Rochd University Hospital for patients’ recruitment and assistance of patient’s appointments. Our gratitude
goes also to Dr. Ibrahim Idbelkass from Nuclear Medicine Department from his assistance in FDG-PET/CT data files’ management.

Funding information

This study was funded by the Institut de Recherche sur le Cancer (IRC) Ref: 201932.

Author Contributions

Affiliations

Laboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco
Amina Gihbid, Imane Elalami, Wafa Khaali, Meriem Khyatti

Laboratory of Pathophysiology, Molecular Genetics and Biotechnology, Faculty of Sciences Ain Chock, Hassan II University, Casablanca, Morocco
Amina Gihbid, Rachida Cadi

Nuclear Medicine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco
Ghofrane Cherkaoui Salhi, Jaafar Ibnohoud, Amal Guensi

Department of Radiology, 20 August 1953 Hospital, University Hospital Center IbnRochd, Hassan II University, Casablanca, Morocco
Belgadir Hasnaa, Naima Elbenna

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
Nezha Tawfiq, Nadia Benchakroun, Karima Bendahhou, Abdellatif Benider

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques Rabat, Morocco
Mohammed El Mzibri

Corresponding author

Correspondence to Meriem Khyatti

Ethical Approval

The study protocol was approved by the Ethics Committee of Ibn Rochd Hospital of Casablanca, Morocco and written informed consent was obtained from each patient. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee on human experimentation and with the Helsinki declaration of 1975, as revised in 1983.
Informed Consent

Informed consent was obtained from all individual participants included in the study.

Availability of data and material

The prospective data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflict of interest statement

The authors declare that they have no competing interests.

References

1. Allal AS, Dulguerov P, Allaoua M, et al (2002) Standardized Uptake Value of 2-[18F] Fluoro-2-Deoxy-d-Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy. JCO 20:1398–1404. https://doi.org/10.1200/JCO.2002.20.5.1398
2. Becker M, Zaidi H (2014) Imaging in head and neck squamous cell carcinoma: the potential role of PET/MRI. Br J Radiol 87:. https://doi.org/10.1259/bjr.20130677
3. Bray F, Ferlay J, Soerjomataram I, et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424. https://doi.org/10.3322/caac.21492
4. Benider A, Harif M, Karkouri M, et al. Registre des Cancers de la région du Grand Casablanca pour la période 2008–2012. Lalla Salma Foundation. 2016. https://www.contrelecancer.ma/site_media/uploaded_les/RCRGC.pdf
5. Brouwer J, Bree R de, Hoekstra OS, et al (2005) Screening for Distant Metastases in Patients With Head and Neck Cancer: Is Chest Computed Tomography Sufficient? The Laryngoscope 115:1813–1817. https://doi.org/10.1097/01.mlg.0000174954.51514.b7
6. Chan S-C, Yeh C-H, Yen T-C, et al (2018) Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 45:1297–1308. https://doi.org/10.1007/s00259-018-3986-3
7. Chan WKS, Mak HKF, Huang B, et al (2010) Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification. Nuclear Medicine Communications 31:206. https://doi.org/10.1097/MNM.0b013e328333e3ef
8. Chen P-J, Yap W-K, Chang Y-C, et al (2020) Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer. BMC Cancer 20:. https://doi.org/10.1186/s12885-020-07044-4
9. Chen W-H, Tang L-Q, Zhang L, et al (2015) Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved
prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. Oncotarget 6:38296–38307. https://doi.org/10.18632/oncotarget.5699

10. Cheng SH, Tsai SYC, Yen KL, et al (2005) Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 61:456–465. https://doi.org/10.1016/j.ijrobp.2004.05.047

11. Chua MLK, Wee JTS, Hui EP, Chan ATC (2016) Nasopharyngeal carcinoma. Lancet 387:1012–1024. https://doi.org/10.1016/S0140-6736(15)00555-0

12. Chung HH, Cheon GJ, Kim J-W, et al (2017) Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix. European Journal of Nuclear Medicine and Molecular Imaging 44:1862–1869. https://doi.org/10.1007/s00259-017-3729-x

13. Cirak K (2011) Are Ratio of Lymph Node to Primary Focus SUV-max and PET/CT 18FDG Standard Uptake Value of Lymph Nodes Meaningful in Staging Non-Small Cell Lung Cancer? UHOD 21:217–222. https://doi.org/10.4999/uhod.10107

14. Fei Z, Chen C, Huang Y, et al (2019) Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma. Medicine (Baltimore) 98:. https://doi.org/10.1097/MD.0000000000016327

15. Goh J, Lim K (2009) Imaging of Nasopharyngeal Carcinoma. 38:8

16. Hung T-M, Fan K-H, Kang C-J, et al (2020) Lymph node-to-primary tumor standardized uptake value ratio on PET predicts distant metastasis in nasopharyngeal carcinoma. Oral Oncology 110:104756. https://doi.org/10.1016/j.oraloncology.2020.104756

17. Jeong Y, Baek S, Park JW, et al (2017) Lymph node standardized uptake values at pre-treatment 18F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma. Br J Radiol 90:20160239. https://doi.org/10.1259/bjr.20160239

18. King AD, Ma BB, Yau YY, et al (2008) The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol 81:291–298. https://doi.org/10.1259/bjr/73751469

19. King AD, Vlantis AC, Yuen TWC, et al (2015) Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. AJNR Am J Neuroradiol 36:2380–2385. https://doi.org/10.3174/ajnr.A4456

20. Lee AWM, Sze WM, Au JSK, et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. International Journal of Radiation Oncology*Biology*Physics 61:1107–1116. https://doi.org/10.1016/j.ijrobp.2004.07.702

21. Li A-C, Xiao W-W, Shen G-Z, et al (2015) Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget 6:24511–24521

22. Li Z, Li Y, Li N, Shen L (2019) Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: An update evidence from 44 studies. Cancer Med 8:67–79. https://doi.org/10.1002/cam4.1882

23. Lin P, Min M, Lee M, et al (2016) Prognostic utility of (18)F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging
24. Liu F-Y, Lin C-Y, Chang JT, et al (2007) 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 48:1614–1619. https://doi.org/10.2967/jnumed.107.043406

25. Lo KW, To KF, Huang DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5:423–428. https://doi.org/10.1016/s1535-6108(04)00119-9

26. Mak HW, Lee SH, Chee J, et al (2015) Clinical Outcome among Nasopharyngeal Cancer Patients in a Multi-Ethnic Society in Singapore. PLoS ONE 10:. https://doi.org/10.1371/journal.pone.0126108

27. Meng K, Tey J, Ho FCH, et al (2020) Utility of magnetic resonance imaging in determining treatment response and local recurrence in nasopharyngeal carcinoma treated curatively. BMC Cancer 20:193. https://doi.org/10.1186/s12885-020-6664-3

28. Mo H-Y, Sun R, Sun J, et al (2012) Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma. Radiat Oncol 7:149. https://doi.org/10.1186/1748-717X-7-149

29. Mohandas A, Marcus C, Kang H, et al (2014) FDG PET/CT in the Management of Nasopharyngeal Carcinoma. American Journal of Roentgenology 203:W146–W157. https://doi.org/10.2214/AJR.13.12420

30. Moon SH, Choi JY, Lee HJ, et al (2015) Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy. Clin Exp Otorhinolaryngol 8:142–148. https://doi.org/10.3342/ceo.2015.8.2.142

31. Ng S-H, Chan S-C, Yen T-C, et al (2009) Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 36:12. https://doi.org/10.1007/s00259-008-0918-7

32. Ou X, Yang Z, Hu C (2014) Use Of 18F-FDG PET/CT In The Diagnosis, Staging, Response Assessment And Prognosis Of Nasopharyngeal Carcinoma: An Updated Review. JOURNAL OF NASOPHARYNGEAL CARCINOMA. https://doi.org/10.15383/jnpc.13

33. Pastor M, Lopez Pousa A, del Barco E, et al (2018) SEOM clinical guideline in nasopharynx cancer (2017). Clin Transl Oncol 20:84–88. https://doi.org/10.1007/s12094-017-1777-0

34. Schulte M, Brecht-Krauss D, Heymer B, et al (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 26:599–605. https://doi.org/10.1007/s002590050427

35. Teo P, Yu P, Lee WY, et al (1996) Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 36:291–304. https://doi.org/10.1016/s0360-3016(96)00323-9

36. Türkölmez Ş, Aksoy SY, Özdemir E, et al (2017) Prognostic Significance of Standardized Uptake Value on 18Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nasopharyngeal Carcinoma. World J Nucl Med 16:33–38. https://doi.org/10.4103/1450-1147.181151

37. Wang KH, Austin SA, Chen SH, et al (2017) Nasopharyngeal Carcinoma Diagnostic Challenge in a Non endemic Setting: Our Experience with 101 Patients. Perm J 21:. https://doi.org/10.7812/TPP/16-180
38. Wei J, Pei S, Zhu X (2016) Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis. Oral Oncol 52:11–17. https://doi.org/10.1016/j.oraloncology.2015.10.010

39. Wu VWC, Leung W-S, Wong K-L, et al (2016) The impact of positron emission tomography on primary tumour delineation and dosimetric outcome in intensity modulated radiotherapy of early T-stage nasopharyngeal carcinoma. Radiat Oncol 11:109. https://doi.org/10.1186/s13014-016-0685-8

40. Xie P, Yue J-B, Fu Z, et al (2010) Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21:1078–1082. https://doi.org/10.1093/annonc/mdp430

41. Xu C, Zhang Y, Peng L, et al (2017) Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients. J Cancer 8:1238–1248. https://doi.org/10.7150/jca.18361

Figures

Figure 1
Time-dependent receiver operating characteristic curve analysis of OS prediction based on the T-SUV max, N-SUV max and NTR in patients with NPC. The area under the curve was 0.48 (p < 0.36, 95% CI 0.36–0.61), and 10.5 was determined as the best T-SUV max cutoff value for survival prediction. The area under the curve was 0.67 (p < 0.05, 95% CI 0.56–0.79), and 7.9 was determined as the best N-SUV max cutoff value for survival prediction. The area under the curve was 0.70 (p < 0.001, 95% CI 0.59–0.81), and 0.82 was determined as the best NTR cutoff value for survival prediction.